udayk
☆    

India,
2019-10-04 12:06

Posting: # 20664
Views: 1,129
 

 Bicalutamide having Long Half Life [Design Issues]

Dear All,

We need clarification on study design of BE of Bicalutamide 50mg tablets since, its long half life is around 150 hours and most of the available literatures have shown as parallel BE study with last time point as 672 hours and two-way cross over study with last time point as 672 hours.

Please suggest on study design of BE/BA study with Time-points to cover the AUC.

Regards,
Udaya Kumar K.
Biostatistician
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2019-10-07 14:59

@ udayk
Posting: # 20674
Views: 901
 

 Bicalutamide: Crossover not realistic

Hi Udaya,

» We need clarification on study design of BE of Bicalutamide 50mg tablets since, its long half life is around 150 hours and most of the available literatures have shown as parallel BE study with last time point as 672 hours and two-way cross over study with last time point as 672 hours.

I can only give what I found in my study: Parallel, 60 subjects (30 per arm), 2 dropouts. We aimed at very similar demographics, e.g., the median body weights differed only ½ kg between groups. ;-)
Sampling: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, 42, 48, 72, 168, 336, 504, and 672 hours. End of hospitalization 48 hours.
Bioanalytics: LC/MS-MS, LLOQ 10 ng/mL for R(–) bicalutamide and 5 ng/mL for S(+) bicalutamide. ULOQ 1 µg/mL R(–) and 100 ng/mL (S+).
R(–) was confirmatory and S(+) exploratory. The CVs were ~21% for AUC and ~10% for Cmax (yes, lower than AUC…). x̃ of tmax was 36 h for both treatments with some subjects having tmax at 72 h. Given such late tmax-values I don’t expect that regulators will accept pAUC0–72 as the primary metric of extent of absorption (instead of AUC0–t). I suggest to add ad least sampling at 96 h.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
udayk
☆    

India,
2019-10-10 09:10

@ Helmut
Posting: # 20682
Views: 849
 

 Bicalutamide: Crossover not realistic

Hi Helmut,

Thank you so much for your inputs.

Regards,
Udaya Kumar K.
Biostatistician.
Activity
 Admin contact
20,641 posts in 4,327 threads, 1,437 registered users;
online 56 (0 registered, 56 guests [including 14 identified bots]).
Forum time: 21:41 CEST (Europe/Vienna)

In general, scientific progress calls for no more
than the absorption and elaboration of new ideas 
and this is a call most scientists are happy to heed.    Werner Heisenberg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5